SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 24, 2003

                            DRAGON PHARMACEUTICAL INC
               (Exact Name of Registrant as Specified in Charter)

     Florida                      0-27937                         65-0142474
 (State or Other         (Commission File Number)               (IRS Employer
 Jurisdiction of                                             Identification No.)
  Incorporation)

   1055 Hastings Street, Suite 1900                                   V6E 2E9
     Vancouver, British Columbia                                    (Zip Code)
(Address of Principal Executive Offices)

       Registrant's telephone number, including area code: (604) 669-8817

                                       N/A
          (Former Name or Former Address, if Changed Since Last Report)





Item 7. Financial  Statements and Exhibits
     (c)  Exhibits
          99.1 Press release dated April 24, 2003.

Item 9. Other  Regulation  FD  Disclosure/Results  of  Operations  and Financial
     Condition (Item 12)

The  purpose  of this  current  report on Form 8-K is to  disclose  that  Dragon
Pharmaceutical  Inc.  issued a press  release on April 24, 2003  announcing  and
summarizing its audited  financial  results for the three-month and twelve-month
periods  ending  December 31, 2002. The press release under this Item 9 is being
furnished to meet the requirements of Item 12 of Form 8-K.








                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                             DRAGON PHARMACEUTICAL INC.

Date: April 24, 2003                  By:       /S/Matthew Kavanagh
                                            -----------------------------
                                      Name:        Matthew Kavanagh
                                      Title  Director of Finance and Compliance
                                            (Principal Financial and Accounting
                                                        Officer)